NCT03516123: A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03516123
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known brain or other CNS metastasis that is either symptomatic or untreated
https://ClinicalTrials.gov/show/NCT03516123

Comments are closed.

Up ↑